Dotti Patch, Extended Release
Product Images NDC 72162-2035

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Dotti (NDC 72162-2035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Dotti Estradiol Transdermal System 1)

FDA Label Image

4a (Dotti Estradiol Transdermal System 10)

FDA Label Image

4b (Dotti Estradiol Transdermal System 11)

FDA Label Image

4c (Dotti Estradiol Transdermal System 12)

FDA Label Image

4d (Dotti Estradiol Transdermal System 13)

FDA Label Image

4e (Dotti Estradiol Transdermal System 14)

FDA Label Image

4f (Dotti Estradiol Transdermal System 15)

FDA Label Image

4g (Dotti Estradiol Transdermal System 16)

FDA Label Image

2 (Dotti Estradiol Transdermal System 2)

FDA Label Image

Figure 1 (Dotti Estradiol Transdermal System 3)

FDA Label Image

2 (Dotti Estradiol Transdermal System 4)

This text appears to be a combination of numerical and textual elements that may have originated from a scientific study or clinical trial. It includes dosages for a hormone therapy or treatment called Estradiol, a placebo, and information indicating a statistically significant difference between the two treatments. However, without additional context or proper formatting, it is difficult to provide a more detailed or accurate summary.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 5)

The text shows percentage change from baseline during a treatment period of Estradiol at different dosages (0.025mg/day and 0.0375mg/day) and placebo. The results were obtained at weeks 2, 7, and 104. There is also reference to the state of Lok Lo s oo and Estadol01 mgydy, but it is not clear how this information relates to the rest of the content.*

FDA Label Image

1 (Dotti Estradiol Transdermal System 6)

FDA Label Image

1 (Dotti Estradiol Transdermal System 7)

The text is a product name and instructions for a transdermal system. The system needs to be changed only on specific days of the week (Sun/Wed, Mon/Thu, Tue/Fri, Wed/Sat, Thu/Sun, Fri/Mon, Sat/Tue).*

FDA Label Image

2 (Dotti Estradiol Transdermal System 8)

FDA Label Image

3 (Dotti Estradiol Transdermal System 9)

FDA Label Image

Label (Lbl721622035)

Each DOTTI® transdermal system contains 0.940 mg of estradiol, USP and delivers 0.075 mg/day. It should be kept out of reach of children and is for transdermal use only. The patch should be stored at 20° to 25°C (68° to 77°F), with excursions permitted between 15° to 30°C (59° to 86°F). The patch should be applied immediately after removal from the pouch and not stored unpouched. The package is not child-resistant. The product is available in a package containing 8 systems and can only be obtained with a prescription.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.